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Abstract
Objective
Systemic sclerosis (SSc) is a rare and clinically heterogeneous autoimmune disorder char-
acterised by fibrosis and microvascular obliteration of the skin and internal organs. Organ
involvement mostly manifests after a variable period of the onset of Raynaud’s phenome-
non (RP). We aimed to map the incidence and predictors of pulmonary, cardiac, gastroin-
testinal (GI) and renal involvement in the early course of SSc.
Methods
In the EUSTAR cohort, patients with early SSc were identified as those who had a visit
within the first year after RP onset. Incident SSc organ manifestations and their risk factors
were assessed using Kaplan-Meier methods and Cox regression analysis.
Results
Of the 695 SSc patients who had a baseline visit within 1 year after RP onset, the incident
non-RP manifestations (in order of frequency) were: skin sclerosis (75%) GI symptoms
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(71%), impaired diffusing capacity for monoxide<80% predicted (65%), DU (34%), cardiac
involvement (32%), FVC<80% predicted (31%), increased PAPsys>40mmHg (14%), and
renal crisis (3%). In the heart, incidence rates were highest for diastolic dysfunction, followed
by conduction blocks and pericardial effusion. While the main baseline risk factor for a short
timespan to develop FVC impairment was diffuse skin involvement, for PAPsys>40mmHg it
was higher patient age. The main risk factors for incident cardiac manifestations were anti-
topoisomerase autoantibody positivity and older age. Male sex, anti-RNA-polymerase-III
positivity, and older age were risk factors associated with incident renal crisis.
Conclusion
In SSc patients presenting early after RP onset, approximately half of all incident organ mani-
festations occur within 2 years and have a simultaneous rather than a sequential onset.
These findings have implications for the design of new diagnostic and therapeutic strategies
aimed to ‘widen’ the still very narrow ‘window of opportunity’. They may also enable physi-
cians to counsel and manage patients presenting early in the course of SSc more accurately.
Introduction
Systemic sclerosis (SSc) is a rare and clinically heterogeneous autoimmune disorder. Prevalence
estimates vary around 20 per 100’000 [1]. The connective tissue and small vessels are mostly
affectedwhich leads to the characteristic fibrosis and vascular obliteration of the skin and inter-
nal organs, particularly of the heart, lungs, kidneys and digestive tract [2,3]. In the vast majority
of individuals, SSc starts with the onset of Raynaud’s phenomenon (RP). Skin sclerosis and
internal organ involvement manifest mostly either with a variable temporal interval after RP
onset or simultaneously with RP.
Numerous cross-sectional studies have already assessed the prevalence of internal organ
manifestations and calculated risk factors in patients with established SSc [4–9]. These studies
have demonstrated that the presence of specific autoantibodies in the patient’s serum, the
patient’s sex, and age at SSc onset as well as the extent of skin involvement are associated with
the prevalence and severity of internal organ involvement [4–12].
As internal organ involvement constitutes an important cause of morbidity and mortality,
exact data about the incidence and temporal evolution of their manifestation after RP onset are
essential for physicians, who need to counsel patients and risk stratify them early after SSc diag-
nosis; and for investigators, who design and perform a clinical trial aimed at altering the natural
course of SSc [13–15]. However, only few studies have prospectively assessed the evolution of
SSc-related organ manifestations after the onset of RP. Given the paucity of reliable data, our
aim was to map the incidence of internal organ manifestations early during the course of dis-
ease. By using real-life data from the large and multinational EUSTAR cohort [8,16], we
assessed the acquisition of pulmonary, cardiac, gastrointestinal or renal involvement in patients
who developed SSc no later than 1 year after RP onset.
Patients and Methods
Study population and design
The structure of the multicentre and international, prospective, longitudinal European Sclero-
derma Trials and Research (EUSTAR) database has been describedpreviously [8,16]. Ethics
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approval according to the Declaration of Helsinki has been obtained from all respective con-
tributing centers’ local ethics committees and ethics committee approval for the EUSTAR
study was obtained from the Ethik Kommission Beider Basel (EKBB, now Ethikkommission
Nordwest- und Zentralschweiz, EKNZ). Each participating centre obtained local ethics com-
mittee approval and written informed consent was required to be signed by each patient.
Demographic and disease characteristics were collected between the time of the database
implementation in 2004 and February, 2014. Data were considered for analysis on the condi-
tion that patients were older than 18 years at the time of the visit, and fulfilled the 1980 Ameri-
can College of Rheumatology (ACR) classification for SSc [17]. This dataset is hereafter called
the “entire EUSTAR cohort”. In a second filtering step, the study population was further
restricted to patients who had a baseline visit within the first year after RP onset, in order to
ensure that patients were enrolled early in their disease course. This restricted dataset is hereaf-
ter called “the study population”.
Study outcomes
In the entire EUSTAR cohort, the time between RP onset and the onset of the first non-Ray-
naud's manifestation of SSc (non-RP) was evaluated. In the restricted study population, the
time between RP onset and the onset of various organ manifestations was assessed i.e. skin
involvement (defined as a modifiedRodnan skin score (mRSS)2 points in at least 1 body
area); gastrointestinal (GI) symptoms (defined as the patient reporting either dysphagia,
reflux, early satiety, vomiting, diarrhoea, bloating or constipation); a systolic pulmonary
artery pressure (PAPsys, as estimated by echocardiography)>40 mmHg as a proxy for sus-
pected pulmonary hypertension; a forced vital capacity (FVC) <80% of predicted as a proxy
for a pulmonary restrictive defect; digital ulcers (DU); cardiac involvement (defined as either
the presence of diastolic dysfunction, conduction blocks, a left ventricular ejection fraction
(LVEF) <50%, or a pericardial effusion); and lastly, renal crisis and erectile dysfunction
(defined as a score<22 points in the International Index of Erectile Function (IIEF-5)
questionnaire) [18]. Table 1 summarises the EUSTAR definitions of the study outcomes
assessed.
Statistical analysis
Frequencies and percentages as well as medians and interquartile ranges (IQR) and means and
standard deviations (SD) were reported for categorical and continuous variables, respectively.
Kaplan-Meier (KM) analyses were carried out to assess the cumulative probabilities of develop-
ing disease features as a function of time after RP onset for cases with available information.
The date of the visit at which organ manifestations were first observedwas used as the end
time, i.e. the incidence. As the first visit was required to be within the first year after RP onset,
manifestations that were already present at the first visit were also regarded as incident. If the
manifestation was never observed, the date of the last follow up visit was set as the censor time.
KM estimates were stratified by sex, age (dichotomized at the median age at RP onset), autoan-
tibody status, and diffuse or limited skin involvement. Patients were classified as having diffuse
or limited skin involvement according to their skin involvement with the first year after RP
onset. Strata were compared with log-rank tests. Furthermore, incidence rates and their 95%
confidence intervals (CI) were calculated. Cox proportional hazards regression analysis was
used to assess the combined effect of the potential risk factors sex, age, autoantibody status and
the extent of skin involvement on diseasemanifestations. All data were analysed with Stata
13.1 (Stata Corporation, College Station, Texas, USA).
Organ Manifestations in Early Systemic Sclerosis
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Results
Patient characteristics
At the time of censoring, a total of 11,290 patients were followed in the EUSTAR database. Of
these patients, 9,891 adult patients fulfilled the 1980 ACR classification criteria for SSc, and were
therefore included in the subsequent analysis of the entire EUSTAR cohort [17]. The study popu-
lation, consisting of patients with a baseline visit within the first year after RP onset, was com-
posed of 695 subjects (Fig 1) with a median observation time of 2.1 years (IQR 0.7–4.6;mean 3.1
years, SD 3.0). The median age of the study population was 52.7 years (IQR 42.3–62.5) at RP
onset, 27% were men (Table 2). The other patients followed in the entire EUSTAR cohort were on
average about 9 years older and about 13% of these were male (Table 2). Compared to the study
population, a higher percentage of the other patients followed in the entire EUSTAR cohort was
ACA positive and a lower percentage had anti-TOPO or anti-RNAP-III autoantibodies (Table 2).
Evolution of first non-RP manifestation of SSc in the entire EUSTAR
cohort
In the entire EUSTAR cohort around 87% of patients had their first non-RP feature of the dis-
ease either after RP onset, or simultaneously with RP onset. The median time from RP onset
until the first non-RP manifestation of SSc was 0.9 years (IQR 0–4.2), with 90% of patients
acquiring their first non-RPmanifestation within 12.0 years (95%CI 89.5–90.8; Fig 2A). Men
developed the first non-RP manifestation faster than women (Fig 2B), and older patients were
affected faster than younger patients (Fig 2C). Patients with anti-RNAP-III and anti-TOPO
autoantibodies were more likely to develop a non-RP manifestation faster than patients with
ACA (Fig 2D). A multivariable analysis confirmed the aforementioned risk factors for disease
onset (data not shown).
Table 1. Definitions of study outcomes.
Study outcome Description
Skin involvement A modified Rodnan skin score of 2 or more points in at least 1 body area.
Gastrointestinal symptoms Any of dysphagia, reflux, early satiety, vomiting, diarrhoea, bloating and/
or constipation as reported by the patient.
Elevated systolic pulmonary
artery pressure
A systolic pulmonary artery pressure as estimated by echocardiography
of more than 40 mmHg as a proxy for suspected pulmonary
hypertension.
Impaired forced vital capacity A forced vital capacity of less than 80% of predicted as a proxy for a
pulmonary restrictive defect.
Digital ulcers Current ulcers distal to or at the proximal interphalangeal joint not
thought to be due to trauma.
Cardiac involvement Any of diastolic dysfunction, conduction blocks, impaired left ventricular
ejection fraction and/or pericardial effusion.
Diastolic dysfunction As estimated by echocardiography.
Conduction blocks Atrioventricular block, bundle branch blocks as assessed by
electrocardiography.
Impaired left ventricular
ejection fraction
A left ventricular ejection fraction less than 50% as estimated by
echocardiography.
Pericardial effusion A pericardial effusion of 5mm or more as estimated by
echocardiography.
Renal crisis Scleroderma renal crisis as per scleroderma expert judgement.
Erectile dysfunction A score of less than 22 points in the International Index of Erectile
Function questionnaire [18].
doi:10.1371/journal.pone.0163894.t001
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Evolution of any organ involvement in the study population
Among the study population, the probability of developing any organ involvement varied
among the different organ systems (Fig 3). More than 90% of patients in the study population
developed either a skin involvement, GI symptoms, or a single breath diffusing capacity for
monoxide (DLCO)<80% of predicted, the majority of patients within the first year. The inci-
dence rates of DU, cardiac involvement and FVC<80% of predicted were considerably lower;
PAPsys>40 mmHg and renal crisis were least frequent.
Pulmonary complications. There was no evidence that the frequency and the time to
develop a FVC<80% of predicted were influenced by the patient’s sex and age (Fig 4A and 4B).
There were however differences according to the serum autoantibody status (Fig 4C) as
patients harbouring anti-TOPO autoantibodies had a significantly higher incidence of
FVC<80% of predicted than patients with anti-RNAP-III autoantibodies (incidence ratio 3.6,
95%CI 1.2–17.9), and with ACA (incidence ratio 4.7, 95%CI 2.3–10.7). Patients with diffuse
skin involvement within the first year after RP onset also more frequently had a FVC<80% of
predicted than patients with limited skin involvement (incidence ratio 2.8, 95%CI 1.8–4.3; Fig
4D). In multivariable analysis, diffuse skin involvement within the first year after RP onset was
the only significant risk factor for incident FVC<80% of predicted (Table 3).
A FVC<50% of predicted (i.e. a severe pulmonary restrictive defect) was diagnosed in 2% (95%
CI 1–5) of patients within the first year and in 12% (95%CI 6–23) during the 10-year follow up.
The probability to develop a DLCO<80% of predicted was high (Fig 3). In multivariable
analysis, anti-TOPO positivity as well as a diffuse skin involvement were the main risk factors
for incident DLCO<80% of predicted (HR 1.60, 95%CI 1.12–2.28; HR 1.52, 95%CI 1.14–2.02,
respectively).
In the first 3 years after RP onset, about one third of patients acquired a DLCO<50% of pre-
dicted (95%CI 27–36), with a progressive increase to 54% of patients (95%CI 44–65) during
the observational period.Older patients, male patients, patients with anti-TOPO autoantibod-
ies, or with diffuse skin involvement had a higher incidence of DLCO<50% of predicted
Fig 1. Flow chart of patients included and excluded in the analysis.
doi:10.1371/journal.pone.0163894.g001
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(incidence ratios: older vs. younger 1.8, 95%CI 1.3–2.5; male vs. female 1.9, 95%CI 1.4–2.6;
anti-TOPO vs. ACA 3.6, 95%CI 2.0–6.49 diffuse vs. limited 2.9, 95%CI 2.0–4.2). However, only
older age, the presence of anti-TOPO autoantibodies and diffuse skin involvement were con-
firmed risk factors for developing a DLCO<50% of predicted in multivariable analysis (HR
1.03 per 1 year increase of age, 95%CI 1.01–1.04; HR 2.64, 95%CI 1.23–5.64; HR 2.06, 95%CI
1.19–3.56, respectively).
The time to develop a PAPsys>40 mmHg was not associated with the patient’s sex or the
patient’s extent of skin involvement (Fig 4E and 4H). Older patients however acquired a
PAPsys>40 mmHg faster and more frequently than younger patients (Fig 4F). Patients with
anti-RNAP-III autoantibodies showed a PAPsys>40 mmHg less frequently than patients har-
bouring ACA or anti-TOPO autoantibodies, but there was no statistically significant difference
(Fig 4G). Patient’s older age was confirmed to be the main risk factor for developing
PAPsys>40 mmHg (Table 3).
Cardiac involvement. There was no evidence that a patient’s sex was associated with the
time to cardiac involvement (Fig 4L). Older patients, however, had a 2.1-fold higher incidence
Table 2. Comparison of disease characteristics at the baseline visit between patients included in this analysis (visit within 1 year after onset of
RP, study population) and those excluded (no visit within 1 year after onset of RP). ACA, anti-centromere autoantibodies; ANA, anti-nuclear autoanti-
bodies; anti-RNAP-III, anti-RNA-polymerase-III autoantibodies; anti-TOPO, anti-topoisomerase-I autoantibodies; DLCO, single breath diffusing capacity for
monoxide; FVC, forced vital capacity; IQR, interquartile range; mRSS, modified Rodnan skin score; PAPsys, systolic pulmonary artery pressure as esti-
mated by echocardiography; RP, Raynaud’s phenomenon; SD, standard deviation.
Patient characteristics at baseline visit n# Included Excluded P-Value
Number of patients 695 695 9196
Age at onset of RP, years; mean (SD) 695 51.7 (14.2) 42.4 (14.8) <0.001
Male, % 695 26.6 13.3 <0.001
Laboratory parameters per patient
ANA, % 683 96.1 96.4 0.67
ACA, % 648 16.7 34.7 <0.001
Anti-TOPO, % 659 42.0 33.2 <0.001
Anti-RNAP-III*, % 317 9.5 2.9 <0.001
Disease characteristics at baseline
Age at onset of first non-RP, years; mean (SD) 607 50.9 (14.4) 46.3 (14.1) <0.001
Digital ulcers, % 684 28.4 34.2 0.002
Puffy fingers*, % 375 52.7 37.3 <0.001
mRSS; median (IQR) 643 10.0 (4.0–19.0) 6 (3.0–12.0) <0.001
Diffuse cutaneous involvement*, % 327 20.6 9.0 <0.001
FVC*, % of predicted; mean (SD) 294 90.3 (19.3) 93.5 (21.4) 0.01
DLCO, % of predicted; mean (SD) 500 68.9 (20.8) 68.9 (20.6) 0.99
PAPsys*, mmHg; mean (SD) 242 30.2 (12.3) 30.6 (13.2) 0.63
Diastolic dysfunction, % 621 15.0 17.7 0.08
Conduction blocks, % 629 8.9 10.7 0.15
Left ventricular ejection fraction*, %; mean (SD) 284 62.8 (6.4) 62.1 (6.7) 0.12
Pericardial effusion*, % 286 8.4 6.0 0.11
Oesophageal symptoms, % 692 56.7 66.2 <0.001
Stomach symptoms, % 686 19.2 24.4 0.003
Intestinal symptoms, % 688 16.9 24.5 <0.001
Renal crisis, % 687 2.6 2.0 0.28
* Data were only captured by EUSTAR since 2007.
# Number of patients with available information for each variable.
doi:10.1371/journal.pone.0163894.t002
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(95%CI 1.5–3.0; Fig 4J) and patients with diffuse skin involvement had a 1.9-fold higher inci-
dence (95%CI 1.3–2.7) of cardiac involvement than patients with limited skin involvement (Fig
4L). Patients with anti-TOPO autoantibodies developed cardiac involvement more frequently
and more rapidly than patients with ACA (incidence ratio 3.7, 95%CI 2.0–7.4; Fig 4K). In mul-
tivariable analysis older age and the presence of anti-TOPO autoantibodies remained risk fac-
tors for any cardiac involvement (HR 1.04 per 1 year increase of age and 3.90, respectively;
Table 3).
The most commonmanifestation of cardiac involvement was diastolic dysfunction (Fig 5).
The incidence of diastolic dysfunction did not differ between sexes and autoantibody status
(incidence ratios: male vs. female 1.0, 95%CI 0.6–1.6; ACA vs. anti-TOPO 0.5, 95%CI 0.2–1.1;
ACA vs. anti-RNAP-III 0.5, 95%CI 0.2–1.8); though the incidence of diastolic dysfunctionwas
3.5 times (95%CI 2.1–5.9) higher in older than in younger patients. The frequency and the
time to develop a diastolic dysfunctionwere also influenced by the extent of skin involvement
with diffuse patients having a 2.1-fold higher incidence (95%CI 1.3–3.4). In the multivariable
Fig 2. Kaplan-Meier curves with 95% CI of the manifestation of any first non-RP feature after RP onset in all SSc
patients in the entire EUSTAR cohort (A) and stratified by sex (B), the median age at RP onset (C) and the
autoantibody status (D). CI, confidence interval; RP, Raynaud’s phenomenon; Pts, patients; ACA, anti-centromere
autoantibodies; anti-TOPO, anti-topoisomerase-I autoantibodies; anti-RNAP-III, anti-RNA-polymerase-III
autoantibodies; hash marks represent censored observations.
doi:10.1371/journal.pone.0163894.g002
Organ Manifestations in Early Systemic Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0163894 October 5, 2016 7 / 15
analysis, however, only older age remained a risk factor for diastolic dysfunction (HR 1.08 per
1 year increase of age; Table 3).
Conduction blocks were the secondmost frequent type of heart involvement (Fig 5). The
incidence did neither vary by patient’s sex, patient’s age, nor the patient's extent of skin
involvement; but patients with anti-TOPO autoantibodies had a considerably higher incidence
of conduction blocks than patients with ACA (incidence ratio 10.0, 95%CI 2.5–86.2). In multi-
variable analysis, patients with anti-TOPO autoantibodies and patients with RNAP-III autoan-
tibodies had an increased risk for conduction blocks, although for the latter, this was not
statistically significant (Table 3).
Pericardial effusionwas one of the less frequent types of heart involvement. This complica-
tion evolvedmore frequently and more rapidly in men, compared to women (incidence ratio
2.7, 95%CI 1.4–5.4) and in patients with diffuse compared to limited skin involvement (inci-
dence ratio 5.6, 95%CI 2.3–16.5). There was no evidence for a difference between age strata. It
is noteworthy, that none of the patients with ACA developed a pericardial effusion, compared
to 26% (95%CI 17–39) of patients with anti-TOPO autoantibodies. In multivariable analysis,
neither patient’s sex nor the extent of skin involvement were confirmed as significant risk fac-
tors (Table 3).
During the first 3 years after RP onset, a LVEF<50% was only observed in 5% of patients
(95%CI 3–9; Fig 5).
Gastrointestinal symptoms. GI symptoms was one of the most common disease features;
at baseline 57% of patients reported oesophageal symptoms, 19% stomach symptoms and 17%
Fig 3. Kaplan-Meier curves of incident organ involvement in SSc patients of the study population after RP
onset. RP, Raynaud’s phenomenon; Pts, patients; DLCO, single breath diffusing capacity for monoxide; GI
symptoms, gastrointestinal symptoms, defined as a history of either dysphagia, reflux, early satiety, vomiting,
diarrhoea, bloating or constipation; Skin involvement, defined as a modified Rodnan skin score of2 at any part of
the body; Cardiac involvement, defined as either the presence of diastolic dysfunction, conduction blocks, a left
ventricular ejection fraction (LVEF) < 50%, or a pericardial effusion; FVC, forced vital capacity; PAPsys, systolic
pulmonary artery pressure as estimated by echocardiography.
doi:10.1371/journal.pone.0163894.g003
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intestinal symptoms. There was no evidence for a difference in the cumulative percentages of
GI symptoms when stratifying by sex, or autoantibody status (p = 0.66 and p = 0.16, respec-
tively). However, older patients and patients with diffuse skin involvement tended to acquire a
GI symptoms earlier and more frequently (p = 0.02 and p = 0.02, respectively). In multivariable
analysis, older age was a borderline risk factor (HR 1.01 per 1 year increase in age, 95%CI 1.00–
1.02) in contrast to diffuse skin involvement (diffuse vs. limited: HR 1.35, 95%CI 1.04–1.76); in
addition, patients with anti-RNAP-III were less likely to develop GI symptoms than patients
Fig 4. Kaplan-Meier curves with 95% CI of incident pulmonary restriction (FVC<80% of predicted; (A-D)), suspected
pulmonary hypertension (PAPsys>40 mmHg; (E-H)), cardiac involvement (I-L) and renal crisis (M-P) after RP onset in
SSc patients of the study population; stratified by sex (A/E/I/M), the median age at RP onset (B/F/J/N), autoantibody
status (C/G/K/O) and extent of skin involvement within the first year after RP onset (D/H/L/P). CI, confidence interval;
FVC, forced vital capacity; PAPsys, systolic pulmonary artery pressure as estimated by echocardiography; cardiac
involvement, defined as either the presence of diastolic dysfunction, conduction blocks, a left ventricular ejection fraction
(LVEF)<50%, or a pericardial effusion; RP, Raynaud’s phenomenon; yrs, years; ACA, anti-centromere autoantibodies;
Anti-TOPO, Anti-topoisomerase-I autoantibodies; Anti-RNAP-III, anti-RNA-polymerase-III autoantibodies; hash marks
represent censored observations.
doi:10.1371/journal.pone.0163894.g004
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with ACA or anti-TOPO autoantibodies (HR 0.55, 95%CI 0.34–0.90; HR 0.59, 95%CI 0.39–
0.91, respectively).
Urogenital involvement. Around 3% (95%CI 2–5) of patients developed a renal crisis
within 1 year after the onset of RP (Fig 3). The majority of patients who developed a renal crisis
did so within the first 4 years. Men had a 2.5 times (95%CI 1.2–5.2) higher incidence than
women (Fig 4M). There was no difference between younger and older patients (Fig 4N). The
cumulative percentage of renal crisis variedmarkedly between the autoantibody groups (Fig
4O). Patients with anti-RNAP-III autoantibodies had a 4.6 times (95%CI 1.6–12.4) higher inci-
dence of renal crisis than patients harbouring anti-TOPO and none of the patients with ACA
developed a renal crisis. Patients with diffuse skin involvement developed a renal crisis earlier
and more frequently than patients with a limited skin involvement (Fig 4P). In multivariable
analysis male sex, anti-RNAP-III positivity, and older age conferred independent risk factors
for renal crisis (Table 3).
The IIEF-5 questionnaire was not included in the EUSTAR database at its inauguration. As
a consequence, data on erectile dysfunctionwas only available for 17% (n = 32) of men in the
study population. Around 52% (95%CI 36–70) of these patients reported an erectile dysfunc-
tion (IIEF-5 score<22) during the first 3 years after RP onset progressing to 95% (95%CI 79–
100) during the subsequent 6 years. In the first 3 years after onset of RP, about 30% (95%CI
18–52) of the men had developed a severe erectile dysfunction (IIEF-5 score<8). Owing to the
small number of men with data on erectile dysfunction, no further stratification was feasible.
Discussion
This longitudinal study uniquely analysed the incidence of organ manifestations in a large
cohort of SSc patients early after RP onset and details differences in the evolution of organ
involvement. Whereas other investigators have analysed the risk factors for diseasemanifesta-
tion in patients at risk for SSc (“pre-SSc”, “very early SSc”), the present study has focused on
the analysis of incident organ manifestations in established disease [19,20].
Table 3. Cox multivariable regression analysis of risk factors for the time to incident FVC<80% of predicted, PAPsys>40 mmHg, any cardiac dys-
function, diastolic dysfunction, conduction block, pericardial effusion and renal crisis. ACA, anti-centromere autoantibodies; Anti-RNAP-III, anti-
RNA-polymerase-III autoantibodies; Anti-TOPO, anti-topoisomerase-I autoantibodies; cardiac involvement, defined as either the presence of diastolic dys-
function, conduction blocks, left ventricular ejection fraction (LVEF)<50%, or pericardial effusion; CI, confidence interval; FVC, forced vital capacity; HR, haz-
ard ratio; PAPsys, systolic pulmonary artery pressure as estimated by echocardiography; RP, Raynaud’s phenomenon.
FVC<80% of
predicted
PAPsys
>40mmHg
Any cardiac
involvement
Diastolic
dysfunction
Conduction block Pericardial
effusion
Renal Crisis
HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI
Sex
Male 1 1 1 1 1 1 1
Female 1.30 0.75–2.25 0.40 0.17–0.93 0.85 0.52–1.38 1.09 0.54–2.22 2.12 0.85–5.28 0.46 0.19–1.13 0.39 0.15–0.97
Age at onset of
RP (in years)
1.01 0.99–1.03 1.09 1.05–1.13 1.04 1.02–1.06 1.08 1.04–1.11 1.01 0.99–1.04 1.02 0.98–1.06 1.04 1.00–1.08
Autoantibody status
ACA 1 1 1 1 1 -* - -* -
Anti-TOPO 2.37 0.80–7.03 2.04 0.61–6.80 3.90 1.82–8.35 1.78 0.61–5.20 17.59 3.81–81.33 1 1
Anti-RNAP-III 0.62 0.13–2.91 0.49 0.05–4.76 2.56 0.91–7.19 2.09 0.55–8.00 6.62 0.88–49.95 0.31 0.04–2.31 5.18 2.03–13.22
Extent of skin involvement
Limited 1 1 1 1 1 1 1
Diffuse 3.08 1.43–6.62 0.91 0.33–2.50 0.93 0.52–1.64 1.78 0.72–4.38 0.45 0.21–0.95 2.86 0.65–12.51 2.96 0.68–12.81
* no patient with ACA developed a renal crisis or pericardial effusion.
doi:10.1371/journal.pone.0163894.t003
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Skin sclerosis, symptoms of GI tract and a reduced pulmonary diffusing capacity were fre-
quent complications of early SSc, incident cardiac complications and pulmonary restriction
were observedmore rarely, followed by elevated systolic pressures of the pulmonary artery and
renal crisis. Our study also highlights a high incidence of diastolic dysfunction, whereas other
cardiac complications (conduction blocks, pericardial effusion and left ventricular systolic dys-
function) were less frequent [21].
In every organ system analysed, approximately half of all organ manifestations that
occurredduring the 10 year observation period became evident within the first 2 years after RP
onset. Thus, the disease onset followed a simultaneous rather than sequential manifestation
pattern. Regardless of the differences in the observed frequencies, i.e. the height of the cumula-
tive incidences, of these manifestations, the steep increase in manifestations during the first
two years after RP onset were persistently observed across all organs manifestations studied;
even complications which are regarded as more severe were not restricted to later disease.
Another important point is that approximatively 75% of the patients develop organ involve-
ment during the 5 first years of the disease. This is good news for the patients who reach that
point without any organ involvement.
In line with retrospective prevalence estimates, there were differences in the risk factors gov-
erning the onset of organ complications [8,11,22–26]. These risk factors modified the cumula-
tive incidences of the organ manifestations but did not substantially modify the steep increase
in manifestation rates during the first 2 years after RP onset. This observation, together with
the short interval between RP onset and the first non-RPmanifestation demonstrates rapid ini-
tial disease kinetics and suggests a relatively short ‘window of opportunity’ to prevent incident
Fig 5. Kaplan-Meier curves of incident cardiac manifestations after RP onset in SSc in the study
population. RP, Raynaud’s phenomenon; Pts, patients; LVEF, left ventricular ejection fraction; hash marks
represent censored observations.
doi:10.1371/journal.pone.0163894.g005
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organ damage [27]. Other investigations have also suggested that a variety of severe organ com-
plications (pulmonary hypertension and lung fibrosis, among others) are not restricted to late
disease [25,28].
The large number of SSc patients and the longitudinal and multinational setup of this study
are strengths of this investigation. Our study also uniquely simulated an inception cohort by
including only patients into the study population who had a baseline visit within the first year
after RP onset. At the same time we introduced a selection bias, as evidencedby the high preva-
lence of factors commonly associated with more prevalent and severe organ complications
(male sex, older age at SSc onset and anti-TOPO autoantibodies) [8,10,22,29,30]. This patient
selection could account for the previously unreported association of male sex and renal crisis
identified in this study and underlines that our findings are specific to SSc patients who present
with SSc early after RP onset and must not be generalized to all individuals who present with
SSc. However, as also demonstrated in this study, more than half of all patients in the entire
EUSTAR cohort experienced their first non-RP feature of the disease within one year of the
onset of RP. It must be also noted, that some SSc patients had documented organ manifesta-
tions already at their baseline visit, leading to an overestimation of the time to its onset. Lastly,
our data may be biased by centre specific differences in the assessment of some organ manifes-
tations. With regard to diastolic dysfunction for example, different diagnostic approaches are
available, each differing in sensitivity and specificity and predictive value [31]. Also, the in the
EUSTAR database the DLCO collected is not corrected for haemoglobin.
Despite these limitations, our data will likely improve the counselling and management of SSc
patients early after RP onset. Our findings also have implications for the design of new diagnostic
strategies and therapeutics aimed to ‘widen’ the still very narrow ‘window of opportunity’ [27].
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